Endo Gains Alexza’s Inhalation Therapy To Deliver Fentanyl For Pain Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Endo assumes responsibility for North American clinical development and regulatory filings for Alexza’s AZ-003.
You may also be interested in...
Alexza Moves Lead Candidate AZ-004 Into Phase III For Agitation In Schizophrenia
Firm targets first half of 2010 for NDA filing, R&D Head James Cassella tells "The Pink Sheet" DAILY.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.